For non-small cell lung cancers (NSCLCs), capmatinib [19], tepotinib [20], and crizotinib [21] are currently recommended for patients with high-level MET amplification or MET exon 14 skipping mutations in the US. Here, MET is linked to non-small cell lung carcinoma.